Abstract: Oligonucleotide sequences encoding gp120 polypeptides from breakthrough isolates of vaccine trials using MN-rgp120 and the encoded gp120 polypeptides are provided. Use of the gp120 polypeptides from one or more of the isolates in a subunit vaccine, usually together with MN-rgp120, can provide protection against HIV strains that are sufficiently different from the vaccine strain (e.g.; MN-rgp120) that the vaccine does not confer protection against those strains. Antibodies induced by the polypeptides are also provided.

Abstract: This invention relates to an SRSV detection kit comprising all antibodies against SRSV-related which makes it possible to detect most SRSV-related viruses and further to distinguish their serotypes and genogroups.

Abstract: Methods are provided for inhibiting or suppressing viral replication in an infected host cell. More specifically, methods are provided for inhibiting or suppressing viral replication in an infected host cell by administering compounds that interfere with the binding of C-X-C chemokines to C-X-C chemokine receptors. Such methods are advantageous for treating viral infections such as human immunodefeciency virus infections.

Abstract: An oligonucleotide useful for detection of an RNA derived from HIV-1 consisting of at least 10 consecutive bases in any of SEQ ID NOS:1, 2, 4 to 10 and 13 to 17, which can bind to a specific site of the RNA.

Abstract: In vitro methods for making a recombinant adenoviral genome, as well as kits for practicing the same and the recombinant adenovirus vectors produced thereby, are provided. In the subject methods, the subject genomes are prepared from first and second vectors. The first vector includes an adenoviral genome having an E region deletion and three different, non-adenoviral restriction endonuclease sites located in the E region. The second vector is a shuttle vector and includes an insertion nucleic acid flanked by two of the three different non-adenoviral endonuclease sites present in the first vector. Cleavage products are prepared from the first and second vectors using the appropriate restriction endonucleases. The resultant cleavage products are then ligated to produce the subject recombinant adenovirus genome. The subject adenoviral genomes find use in a variety of applications, including as vectors for use in a variety of applications, including gene therapy.

Abstract: The present invention is based on the discovery of a composition that provides targeted ubiquitination. Specifically the composition contains an ubiquitin pathway protein binding moiety which recognizes an ubiquitin pathway protein and a targeting moiety which recognizes a target protein. In addition, the present invention provides libraries of compositions, where each composition contains an ubiquitin pathway protein binding moiety and a member of a molecular library. The libraries of the present invention can be used to identify proteins involved in a predetermined function of cells.

Abstract: In general, the invention features antibodies specific for PrPSc and diagnostic, therapeutic, and decontamination uses thereof. The invention also features synthetic peptides useful as immunogens for generating antibodies specific for PrPSc and therapeutic for the treatment of prion diseases.

Abstract: The invention provides isolated nucleic acids molecules, designated COCH5B2 nucleic acid molecules, which encode polypeptides involved in inner ear biology. The invention also provides antisense nucleic acid molecules, expression vectors containing COCH5b2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a COCH5b2 gene has been introduced or disrupted. The invention still further provides isolated COCH5B2 polypeptides, fusion polypeptides, antigenic peptides, and anti-COCH5B2 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: Immunogenic preparations and vaccines, in particular which are inactivated, effective against feline calicivirosis, based on an FCV virus strain 431 as deposited at the CNCM under the accession number CNCM I-2166, or one of its equivalents, in a veterinarily acceptable vehicle or excipient, preferably combined with FCV virus obtained from another FCV strain, in particular strain G1 as deposited at the CNCM under the accession number CNCM I-2167.

Abstract: The present invention relates to polypeptides encoded by a nucleotide sequence from an HIV-1, HIV-2, or SIV viral genome, in which the nucleotide sequence is amplified from the viral genome using a pair of primers that contain sequences that are conserved between different HIV and SIV strains. The primers are insensitive to variations in the genomes of different HIV and SIV isolates and, therefore, can be used to amplify nucleotide sequences from HIV-1, HIV-2, and SIV strains. The invention also relates to antibodies directed against these polypeptides and methods and kits for diagnosing viral infection.

Abstract: The invention concerns a method for in vitro propagation of the agent responsible for transmissible spongiform encephalopathies, or prion, comprising steps which consist in: providing a culture or a glial cell line and in infecting the culture or line with the agent responsible for transmissible spongiform encephalopathies or prion. Said method enables to obtain infected cell line capable of being used to assess the efficacy of a molecule in the reduction or inhibition of the infectiosity of the prion or for detecting the prion.

Abstract: The present invention relates to FMDC vaccine based on peptides having a sequence of at least 8 amino acids, which corresponds to a partial sequence of the non-structural protein region of FMDV, which was selected by immunoreactivity with FMDV-specific antibodies or by immunoreactivity with FMDV-specific T lymphocytes, and to their production and their use.

Abstract: Recombinant expression vectors and methods are provided for detecting HIV and monitoring HIV drug resistance.

Abstract: A method of inhibiting viral gene activities (and cellular gene activities) is disclosed. In one embodiment, the method comprises the step of delivering an effective amount of an inhibitor of a viral looping/linking factor to an infected patient.

Abstract: Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transfering heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication-competant helper virus.

Abstract: The present invention provides methods of preventing or treating West Nile virus as well as infections caused by other viruses of the Flaviviridae family in animals comprising administering to the animal an effective amount of ribavirin and/or interferon alpha-2b.

Abstract: Isolated and purified proteins and nucleic acids including a novel member of the immunoglobulin super-family characterized as having SHP-2 binding activity and cell signaling activity and called protein zero related or PZR, and cDNA encoding the same. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to PZR, and methods of producing the same, are also disclosed. PZR is characterized as having SHP-2 binding activity and cell signaling activity and thus, therapeutic methods involving these activities are also disclosed.

Abstract: A preparation of U binding protein (Ubp) and a gene sequence encoding Ubp and an anti-Ubp antibody are disclosed. An assay to identify modulators of Ubp/Vpu interaction and Gag/Ubp interaction is also disclosed.

Abstract: The present invention provides a method for constructing a fiber-mutant adenovirus vector in which a foreign peptide is introduced by a simple system into the fiber HI loop-coding gene of adenovirus; and provides a fiber-mutant adenovirus vector which is constructed by this method.

Abstract: The invention provides a novel post-transcriptional regulatory element that can function as an RNA nucleo-cytoplasmic transport element. The invention also provides for an attenuated HIV-1 hybrid virus for use as a vaccine and a kit incorporating the hybrid virus. The kit also includes instructional material teaching the use of the vaccine, where the instructional material indicates that the vaccine is used for the prophylaxis or amelioration of HIV-1 infection in a mammal; that the vaccine is to be administered to a mammal in a therapeutically effective amount sufficient to express a viral protein; where the vaccine will not cause clinically significant CD4+ cell depletion; and, the expression of the viral protein elicits an immune response to the attenuated HIV-1 virus. The invention further provides for a method for screening for post-transcriptional RNA nucleo-cytoplasmic transport element (NCTE) binding proteins.